董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Parkinson | 男 | Independent Director | 69 | 13.08万美元 | 未持股 | 2020-03-27 |
| Michael A. Metzger | 男 | Independent Director | 49 | 14.38万美元 | 未持股 | 2020-03-27 |
| Matthew D. Perry | 男 | Independent Director | 47 | 11.68万美元 | 未持股 | 2020-03-27 |
| Michael A. Metzger | 男 | Independent Director | 49 | 未披露 | 未持股 | 2020-03-27 |
| Adam R. Craig | 男 | Director, Chief Executive Officer, President, Interim Chief Medical Officer | 54 | 170.24万美元 | 未持股 | 2020-03-27 |
| Reed V. Tuckson | 男 | Independent Director | 69 | 13.23万美元 | 未持股 | 2020-03-27 |
| Laurent Fischer | 男 | Chairman of the Board, Independent Director | 56 | 16.53万美元 | 未持股 | 2020-03-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David H. Kirske | 男 | Executive Vice President, Chief Financial Officer and Secretary | 65 | 83.19万美元 | 未持股 | 2020-03-27 |
| Adam R. Craig | 男 | Director, Chief Executive Officer, President, Interim Chief Medical Officer | 54 | 170.24万美元 | 未持股 | 2020-03-27 |
| Bruce J. Seeley | 男 | Executive Vice President and Chief Operating Officer | 55 | 85.95万美元 | 未持股 | 2020-03-27 |
董事简历
中英对照 | 中文 | 英文- David Parkinson
-
David Parkinson，他是New Enterprise Associates的投资合伙人。从2007年到2012年，他担任Nodality（一个南旧金山的生物科技公司）的总裁兼首席执行官。直到2007年，他担任Biogen Idec的高级副总裁，负责肿瘤学研究和开发。从1990年到1997年，他在 the National Cancer Institute任职担任其临床实验药物部门的首席执行官，随后担任癌症治疗评估项目的代理副董事。他是美国食品和药物管理局（the U.S. Food and Drug Administration）生物制剂咨询委员会前主席。他目前担任Threshold Pharmaceuticals and Cerulean Pharma Inc.（公共生物制药公司，专注于抗癌药物的发现和开发）董事会董事。他获得University of Toronto的医学学位。
David Parkinson,has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. He is responsible for the management of the Company, developing objectives, strategy and standards of performance, securing and leading a team of professionals and directing them to deliver the required performance. Dr. Parkinson has more than 30 years of experience in clinical oncology development. Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara and Vectibix. Dr. Parkinson previously served on the Board of CTI Biopharma, Inc. and currently serves as Director on the Board of privately held Angiocrine Bioscience Inc. Dr. Parkinson received his M.D. from the University of Toronto, has previously held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, and has served as Chief of the Investigational Drug Branch and acting Associate Director of the Cancer Therapy Evaluation Program of the National Cancer Institute. He has authored over 100 peer-reviewed publications and is a recipient of the FDA's Cody Medal. - David Parkinson，他是New Enterprise Associates的投资合伙人。从2007年到2012年，他担任Nodality（一个南旧金山的生物科技公司）的总裁兼首席执行官。直到2007年，他担任Biogen Idec的高级副总裁，负责肿瘤学研究和开发。从1990年到1997年，他在 the National Cancer Institute任职担任其临床实验药物部门的首席执行官，随后担任癌症治疗评估项目的代理副董事。他是美国食品和药物管理局（the U.S. Food and Drug Administration）生物制剂咨询委员会前主席。他目前担任Threshold Pharmaceuticals and Cerulean Pharma Inc.（公共生物制药公司，专注于抗癌药物的发现和开发）董事会董事。他获得University of Toronto的医学学位。
- David Parkinson,has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. He is responsible for the management of the Company, developing objectives, strategy and standards of performance, securing and leading a team of professionals and directing them to deliver the required performance. Dr. Parkinson has more than 30 years of experience in clinical oncology development. Prior to joining ESSA, Dr. Parkinson was a Venture Partner at New Enterprise Associates, Inc. and served as the President and CEO of Nodality, Inc., a biotechnology company developing human cell-based translational diagnostic tools. Throughout his career, Dr. Parkinson has held senior roles in clinical oncology development at a number of pharmaceutical and biotech companies, including Biogen, Amgen and Novartis, and has overseen the successful clinical development of a series of cancer therapeutics, including Gleevec, Zometa, Femara and Vectibix. Dr. Parkinson previously served on the Board of CTI Biopharma, Inc. and currently serves as Director on the Board of privately held Angiocrine Bioscience Inc. Dr. Parkinson received his M.D. from the University of Toronto, has previously held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, and has served as Chief of the Investigational Drug Branch and acting Associate Director of the Cancer Therapy Evaluation Program of the National Cancer Institute. He has authored over 100 peer-reviewed publications and is a recipient of the FDA's Cody Medal.
- Michael A. Metzger
-
Michael A. Metzger，自2015年5月起担任Syndax Pharmaceuticals, Inc.总裁兼首席运营官；2013年12月至2014年10月间担任Regado Biosciences, Inc.（曾是上市公司，与Tobira Therapeutics, Inc.合并）的总裁兼首席运营官，2014年10月至2015年5月间担任其总裁兼首席执行官兼董事，于2015年监管公司与Tobira Therapeutics, Inc.的成功合并。此前，他于2011年3月至2013年11月间担任Mersana Therapeutics, Inc.（私营生物制药公司，开发癌症的新型免疫交联物疗法）的执行副总裁兼首席运营官；2006年至2011年2月间担任Forest Laboratories, LLC（被Allergan plc收购）的高级业务开发职位，包括领导并购等，Allergan plc是一家上市公司。自2010年12月起任CTI BioPharma Corp董事此前，他于2001年至2006年间担任Onconova Therapeutics, Inc.的企业发展副总裁；1997年至2001年间担任MESA Partners, Inc.（风险资本公司）的常务董事。他获得了George Washington University的学士学位，和the New York University Stern School of Business的金融学工商管理硕士学位。
Michael A. Metzger is a Class I director who has served as our President and Chief Operating Officer since May 2015 and as a member of our board of directors since July 2019. Prior to joining us, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015 where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Mr. Metzger currently serves on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company, as well as the boards of other private and not-for-profit companies. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business. - Michael A. Metzger，自2015年5月起担任Syndax Pharmaceuticals, Inc.总裁兼首席运营官；2013年12月至2014年10月间担任Regado Biosciences, Inc.（曾是上市公司，与Tobira Therapeutics, Inc.合并）的总裁兼首席运营官，2014年10月至2015年5月间担任其总裁兼首席执行官兼董事，于2015年监管公司与Tobira Therapeutics, Inc.的成功合并。此前，他于2011年3月至2013年11月间担任Mersana Therapeutics, Inc.（私营生物制药公司，开发癌症的新型免疫交联物疗法）的执行副总裁兼首席运营官；2006年至2011年2月间担任Forest Laboratories, LLC（被Allergan plc收购）的高级业务开发职位，包括领导并购等，Allergan plc是一家上市公司。自2010年12月起任CTI BioPharma Corp董事此前，他于2001年至2006年间担任Onconova Therapeutics, Inc.的企业发展副总裁；1997年至2001年间担任MESA Partners, Inc.（风险资本公司）的常务董事。他获得了George Washington University的学士学位，和the New York University Stern School of Business的金融学工商管理硕士学位。
- Michael A. Metzger is a Class I director who has served as our President and Chief Operating Officer since May 2015 and as a member of our board of directors since July 2019. Prior to joining us, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015 where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Mr. Metzger currently serves on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company, as well as the boards of other private and not-for-profit companies. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.
- Matthew D. Perry
-
Matthew D. Perry，2016年1月以来，他担任是我们的董事。他是BVF Partners的总裁和公司管理的底曾的基金投资组合经理。BVF Partners是私人投资的合伙企业，从事小盘股，价值导向的投资机会超过20年。他于1996年12月加入BVF Partners并在许多交易中成功地领导投资者。在他的职业生涯，他对众多生物技术公司的发展方向产生了积极影响。他是Nordic Biotech Advisors ApS（丹麦哥本哈根的风险资本公司）的联合创始人和董事。他获得College of William and Mary的生物学院的学士学位。
Matthew D. Perry has been one of our directors since January 2016. Mr. Perry is the President of BVF Partners L.P. and portfolio manager for the underlying funds managed by the firm. BVF Partners L.P. is a private investment partnership that has focused on small-cap, value oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners L.P. in December 1996 and has been a successful lead investor in dozens of transactions and has positively influenced corporate direction for numerous biotechnology companies during the course of his career. Mr. Perry is also a co-founder and director of Nordic Biotech Advisors ApS, a venture capital firm based in Copenhagen, Denmark. In February 2017 Mr. Perry was appointed to the Board of Directors of Xoma Corporation. He holds a B.S. from the Biology Department at the College of William and Mary. - Matthew D. Perry，2016年1月以来，他担任是我们的董事。他是BVF Partners的总裁和公司管理的底曾的基金投资组合经理。BVF Partners是私人投资的合伙企业，从事小盘股，价值导向的投资机会超过20年。他于1996年12月加入BVF Partners并在许多交易中成功地领导投资者。在他的职业生涯，他对众多生物技术公司的发展方向产生了积极影响。他是Nordic Biotech Advisors ApS（丹麦哥本哈根的风险资本公司）的联合创始人和董事。他获得College of William and Mary的生物学院的学士学位。
- Matthew D. Perry has been one of our directors since January 2016. Mr. Perry is the President of BVF Partners L.P. and portfolio manager for the underlying funds managed by the firm. BVF Partners L.P. is a private investment partnership that has focused on small-cap, value oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners L.P. in December 1996 and has been a successful lead investor in dozens of transactions and has positively influenced corporate direction for numerous biotechnology companies during the course of his career. Mr. Perry is also a co-founder and director of Nordic Biotech Advisors ApS, a venture capital firm based in Copenhagen, Denmark. In February 2017 Mr. Perry was appointed to the Board of Directors of Xoma Corporation. He holds a B.S. from the Biology Department at the College of William and Mary.
- Michael A. Metzger
-
Michael A. Metzger自2010年12月起任公司董事，现在是Mersana Therapeutics公司执行副总裁及首席运营官，该公司是一家专门从事制药开发的制药公司，他从2011年4月起便担任该职务。从2006年9月到2011年3月，Metzger先生任Forest Laboratories公司业务开发高级董事，该公司是一家专门从事制药开发的公司，他在该公司负责合并与收购业务。从2001年到2006年，Metzger先生任Onconova Therapeutics公司企业发展副总裁，该公司是一家临床系统测试制药公司，主要从事肿瘤化合物全新探索和开发。从1997年到2001年，Metzger先生担任Mesa Partners公司常务董事。此外，Metzger先生还在多个生命科学公司担任董事。Metzger先生拥有乔治华盛顿大学学士学位和纽约大学史登商学院工商管理硕士学位。
Michael A. Metzger has been one of our directors since January 2017. Mr. Metzger has served as president and chief operating officer of Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel cancer therapies, since 2015 and as a member of its board of directors since 2019. Mr. Metzger served as president and chief executive officer of Regado Biosciences, Inc., a development stage biotechnology company, from 2013 to 2015. At Regado, he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015 and acted as an adviser to Tobira during its subsequent sale to Allergan in 2016. Previously, Mr. Metzger served as executive vice president and chief operating officer at Mersana Therapeutics, a biotechnology company developing novel immunoconjugate therapies for cancer, from 2011 to 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, Inc. from 2006 to 2011. Mr. Metzger served as vice president of corporate development at Onconova Therapeutics, Inc., from 2001 until 2006 and was a managing director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business. - Michael A. Metzger自2010年12月起任公司董事，现在是Mersana Therapeutics公司执行副总裁及首席运营官，该公司是一家专门从事制药开发的制药公司，他从2011年4月起便担任该职务。从2006年9月到2011年3月，Metzger先生任Forest Laboratories公司业务开发高级董事，该公司是一家专门从事制药开发的公司，他在该公司负责合并与收购业务。从2001年到2006年，Metzger先生任Onconova Therapeutics公司企业发展副总裁，该公司是一家临床系统测试制药公司，主要从事肿瘤化合物全新探索和开发。从1997年到2001年，Metzger先生担任Mesa Partners公司常务董事。此外，Metzger先生还在多个生命科学公司担任董事。Metzger先生拥有乔治华盛顿大学学士学位和纽约大学史登商学院工商管理硕士学位。
- Michael A. Metzger has been one of our directors since January 2017. Mr. Metzger has served as president and chief operating officer of Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel cancer therapies, since 2015 and as a member of its board of directors since 2019. Mr. Metzger served as president and chief executive officer of Regado Biosciences, Inc., a development stage biotechnology company, from 2013 to 2015. At Regado, he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015 and acted as an adviser to Tobira during its subsequent sale to Allergan in 2016. Previously, Mr. Metzger served as executive vice president and chief operating officer at Mersana Therapeutics, a biotechnology company developing novel immunoconjugate therapies for cancer, from 2011 to 2013 and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, Inc. from 2006 to 2011. Mr. Metzger served as vice president of corporate development at Onconova Therapeutics, Inc., from 2001 until 2006 and was a managing director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.
- Adam R. Craig
-
Adam R. Craig, Ph.D.，2012年3月以来，他一直担任我们的执行副总裁负责发展和首席医疗官。从2007年9月到2011年12月，他担任 ChemGenex Pharmaceuticals Ltd.（一个从事于治疗癌症的新治疗药物的发展的生物科技公司）的首席医疗官和类似职务，随后2011年7月公司被ChemGenex by Cephalon, Inc.收购。2011年10月Cephalon, Inc.被 Teva Pharmaceutical Industries Ltd.收购。从2011年12月到加入公司，他担任Teva Pharmaceutical Industries Ltd.的顾问。在加入ChemGenex之前，他是Innovive Pharmaceuticals, Inc.（从事血液学公司）的创始首席医疗官。在加入 Innovive之前，他担任ArQule Inc.、Ilex Oncology Inc.和Antisoma plc。担任职务并不断被提拔。他获得伦敦大学（ London University）医疗资格、利兹大学（the University of Leeds）的分子医学博士学位以及英国 the Open Business School的工商管理硕士学位。他是the Royal College of Pediatrics 和Child Health Physicians UK的成员以及在儿科和儿童肿瘤进行学习的研究生。他目前是德州的癌症预防研究所（the Cancer Prevention Research Institute of Texas，癌症研究和预防项目和服务的基金）商业化审查委员会（the Commercialization Review Council）成员。
Adam R. Craig has served as one of our directors and as our President and Chief Executive Officer since March 2017. Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012 Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. Dr. Craig is a Member of the Royal College of Physicians UK and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the UK and an M.B.A. from the Open Business School in the UK. Dr. Craig has served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. - Adam R. Craig, Ph.D.，2012年3月以来，他一直担任我们的执行副总裁负责发展和首席医疗官。从2007年9月到2011年12月，他担任 ChemGenex Pharmaceuticals Ltd.（一个从事于治疗癌症的新治疗药物的发展的生物科技公司）的首席医疗官和类似职务，随后2011年7月公司被ChemGenex by Cephalon, Inc.收购。2011年10月Cephalon, Inc.被 Teva Pharmaceutical Industries Ltd.收购。从2011年12月到加入公司，他担任Teva Pharmaceutical Industries Ltd.的顾问。在加入ChemGenex之前，他是Innovive Pharmaceuticals, Inc.（从事血液学公司）的创始首席医疗官。在加入 Innovive之前，他担任ArQule Inc.、Ilex Oncology Inc.和Antisoma plc。担任职务并不断被提拔。他获得伦敦大学（ London University）医疗资格、利兹大学（the University of Leeds）的分子医学博士学位以及英国 the Open Business School的工商管理硕士学位。他是the Royal College of Pediatrics 和Child Health Physicians UK的成员以及在儿科和儿童肿瘤进行学习的研究生。他目前是德州的癌症预防研究所（the Cancer Prevention Research Institute of Texas，癌症研究和预防项目和服务的基金）商业化审查委员会（the Commercialization Review Council）成员。
- Adam R. Craig has served as one of our directors and as our President and Chief Executive Officer since March 2017. Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012 Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. Dr. Craig is a Member of the Royal College of Physicians UK and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the UK and an M.B.A. from the Open Business School in the UK. Dr. Craig has served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas.
- Reed V. Tuckson
-
Reed V. Tuckson自2011年9月起担任Henry Schein公司的董事之一。Tuckson博士自2014年起担任私人咨询公司Tuckson Health Connections的董事总经理。2006年12月至2014年3月，Tuckson博士担任Medical Affairs of UnitedHealth Group 执行副总裁兼医疗事务主管，2000年11月至2006年12月，担任Clinical Affairs of UnitedHealth Group临床事务高级副总裁。Tuckson博士还曾担任American Medical Association专业标准高级副总裁、洛杉矶Charles R. Drew医学与科学大学校长、 March of Dimes Birth Defects Foundation项目高级副总裁和Public Health for the District of Columbia专员。他目前在 Alliance for Health Policy, Project Sunshine, LifePoint Health, InformGenomics的董事会任职，在National Academy of Medicine委员会任职，在美国国家医学科学院多个委员会任职。Tuckson博士曾在Acasti Pharma，Inc.担任董事至2017年。塔克森博士在Howard University获得动物学学士学位，在Georgetown University School of Medicine获得医学博士学位，并完成了University of Pennsylvania's General Internal Medicine Residency and Fellowship项目。
Reed V. Tuckson,as the Managing Director of Tuckson Health Connections, LLC since 2013, he focuses on improving healthcare delivery and addressing pressing health challenges through innovative solutions and strategic partnerships.Reed is also a co-founder and convener of the Black Coalition Against COVID-19, an initiative aimed at addressing the disproportionate impact of the COVID-19 pandemic on Black communities and promoting vaccination and public health awareness.Additionally, he serves as the co-founder and Board Chairman of the Coalition For Trust in Health & Science, which works to enhance trust in health information and scientific research among diverse communities. Previously, he was the Executive Vice President and Chief of Medical Affairs at UnitedHealth Group from 2006 to 2013, where he played a critical role in shaping the company's healthcare services and strategies, focusing on quality and patient-centered care.Reed completed his medical training at Georgetown University School of Medicine, earning his Doctor of Medicine (M.D.) degree. He further honed his skills during his residency and fellowship in General Internal Medicine at the University of Pennsylvania Hospital, where he was also a Robert Wood Johnson Foundation Clinical Scholar, studying at the Wharton School of Business to integrate business acumen with healthcare delivery.He holds a Bachelor of Science (B.S.) degree from Howard University. - Reed V. Tuckson自2011年9月起担任Henry Schein公司的董事之一。Tuckson博士自2014年起担任私人咨询公司Tuckson Health Connections的董事总经理。2006年12月至2014年3月，Tuckson博士担任Medical Affairs of UnitedHealth Group 执行副总裁兼医疗事务主管，2000年11月至2006年12月，担任Clinical Affairs of UnitedHealth Group临床事务高级副总裁。Tuckson博士还曾担任American Medical Association专业标准高级副总裁、洛杉矶Charles R. Drew医学与科学大学校长、 March of Dimes Birth Defects Foundation项目高级副总裁和Public Health for the District of Columbia专员。他目前在 Alliance for Health Policy, Project Sunshine, LifePoint Health, InformGenomics的董事会任职，在National Academy of Medicine委员会任职，在美国国家医学科学院多个委员会任职。Tuckson博士曾在Acasti Pharma，Inc.担任董事至2017年。塔克森博士在Howard University获得动物学学士学位，在Georgetown University School of Medicine获得医学博士学位，并完成了University of Pennsylvania's General Internal Medicine Residency and Fellowship项目。
- Reed V. Tuckson,as the Managing Director of Tuckson Health Connections, LLC since 2013, he focuses on improving healthcare delivery and addressing pressing health challenges through innovative solutions and strategic partnerships.Reed is also a co-founder and convener of the Black Coalition Against COVID-19, an initiative aimed at addressing the disproportionate impact of the COVID-19 pandemic on Black communities and promoting vaccination and public health awareness.Additionally, he serves as the co-founder and Board Chairman of the Coalition For Trust in Health & Science, which works to enhance trust in health information and scientific research among diverse communities. Previously, he was the Executive Vice President and Chief of Medical Affairs at UnitedHealth Group from 2006 to 2013, where he played a critical role in shaping the company's healthcare services and strategies, focusing on quality and patient-centered care.Reed completed his medical training at Georgetown University School of Medicine, earning his Doctor of Medicine (M.D.) degree. He further honed his skills during his residency and fellowship in General Internal Medicine at the University of Pennsylvania Hospital, where he was also a Robert Wood Johnson Foundation Clinical Scholar, studying at the Wharton School of Business to integrate business acumen with healthcare delivery.He holds a Bachelor of Science (B.S.) degree from Howard University.
- Laurent Fischer
-
Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.com, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland. - Laurent Fischer自2017年7月以来一直担任我们的董事之一。Fischer博士自2016年11月被Tobira Therapeutics收购以来，一直担任Allergan（一家全球制药公司）肝脏治疗领域的高级副总裁，主管，自2013年起担任首席执行官。Fischer博士自2017年3月起担任Frazier梦百合Partners生命科学团队的高级顾问。他此前曾担任Jennerex，Inc.（一流的肝癌溶瘤免疫疗法公司，被Sillajen公司以1.5亿美元收购）的主席兼首席执行官。他曾担任Ocera Therapeutics公司的联席创始人、总裁兼首席执行官，也曾担任DuPont-Merck公司、DuPont Pharmaceuticals公司、Hoffmann-La Roche公司的肝脏疾病、病毒学和肿瘤学高级职务。Fischer博士还担任MirumPharmaceuticals，Inc.的董事。Fischer博士在日内瓦大学（University of Geneva）获得本科学位，在瑞士日内瓦医学院（Geneva Medical School，Switzerland）获得医学学位。
- Laurent Fischer,has served as a member of the Board since June 2019. Dr. Fischer has served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, since June 2020. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.com, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer currently serves on the boards of directors of public biopharmaceutical companies Adverum and CTI BioPharma Corp., where he serves as Chairman, and privately held biopharmaceutical company Lycia Therapeutics, Inc. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland.
高管简历
中英对照 | 中文 | 英文- David H. Kirske
David H.Kirske于2017年9月首席财务官担任我们的执行Vice President。在此之前，他自2017年8月起担任我们的首席财务和会计官。Kirske先生领导我们的财务，会计和投资者关系团队。在被任命之前，Kirske先生自2013年1月起担任独立的首席财务官首席财务官顾问。Kirske先生的财务管理经验包括监督债务和股权的财务，会计，运营和资本化。在担任顾问之前，Kirske先生曾担任Helix Biomedix的Vice President和首席财务官，管理该公司的所有财务和行政活动。此前，他曾担任F-5Networks公司和Redhook Brewery公司的财务主管兼公司总会计师，在那里他曾管理公司和国际实体，以及领导和执行每个公司成功的首次公开募股的管理团队的一部分。职业生涯早期，他曾担任Cray Computer公司的控制职务。Kirske先生拥有University of Puget Sound的工商管理学士学位。
David H. Kirske,most recently served as the Chief Financial Officer of Stratus Therapeutics from September 2024 to May 2025. From August 2023 to September 2024, Mr. Kirske provided financial strategy for biotechnology companies as part of Madrona Financial Consulting. Prior to that, he served as CTI BioPharma's Executive Vice President, Chief Financial Officer from September 2017 until June 2023. He is a finance, accounting and investor relations leader for public and emerging growth private companies primarily in the biotechnology industry, as well as in technology and manufacturing. His financial management experience includes overseeing finance, accounting, operations and capitalization in debt and equity. Prior to CTI BioPharma, Mr. Kirske served as Vice President and Chief Financial Officer of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporate Controller for F-5 Networks and Redhook Brewery, where he managed corporate and international entities and was part of the management teams that led and executed each company's successful initial public offering. Earlier, he held a controllership position at Cray Computer. Mr. Kirske holds a B.A. in Business Administration from the University of Puget Sound.- David H.Kirske于2017年9月首席财务官担任我们的执行Vice President。在此之前，他自2017年8月起担任我们的首席财务和会计官。Kirske先生领导我们的财务，会计和投资者关系团队。在被任命之前，Kirske先生自2013年1月起担任独立的首席财务官首席财务官顾问。Kirske先生的财务管理经验包括监督债务和股权的财务，会计，运营和资本化。在担任顾问之前，Kirske先生曾担任Helix Biomedix的Vice President和首席财务官，管理该公司的所有财务和行政活动。此前，他曾担任F-5Networks公司和Redhook Brewery公司的财务主管兼公司总会计师，在那里他曾管理公司和国际实体，以及领导和执行每个公司成功的首次公开募股的管理团队的一部分。职业生涯早期，他曾担任Cray Computer公司的控制职务。Kirske先生拥有University of Puget Sound的工商管理学士学位。
- David H. Kirske,most recently served as the Chief Financial Officer of Stratus Therapeutics from September 2024 to May 2025. From August 2023 to September 2024, Mr. Kirske provided financial strategy for biotechnology companies as part of Madrona Financial Consulting. Prior to that, he served as CTI BioPharma's Executive Vice President, Chief Financial Officer from September 2017 until June 2023. He is a finance, accounting and investor relations leader for public and emerging growth private companies primarily in the biotechnology industry, as well as in technology and manufacturing. His financial management experience includes overseeing finance, accounting, operations and capitalization in debt and equity. Prior to CTI BioPharma, Mr. Kirske served as Vice President and Chief Financial Officer of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporate Controller for F-5 Networks and Redhook Brewery, where he managed corporate and international entities and was part of the management teams that led and executed each company's successful initial public offering. Earlier, he held a controllership position at Cray Computer. Mr. Kirske holds a B.A. in Business Administration from the University of Puget Sound.
- Adam R. Craig
Adam R. Craig, Ph.D.，2012年3月以来，他一直担任我们的执行副总裁负责发展和首席医疗官。从2007年9月到2011年12月，他担任 ChemGenex Pharmaceuticals Ltd.（一个从事于治疗癌症的新治疗药物的发展的生物科技公司）的首席医疗官和类似职务，随后2011年7月公司被ChemGenex by Cephalon, Inc.收购。2011年10月Cephalon, Inc.被 Teva Pharmaceutical Industries Ltd.收购。从2011年12月到加入公司，他担任Teva Pharmaceutical Industries Ltd.的顾问。在加入ChemGenex之前，他是Innovive Pharmaceuticals, Inc.（从事血液学公司）的创始首席医疗官。在加入 Innovive之前，他担任ArQule Inc.、Ilex Oncology Inc.和Antisoma plc。担任职务并不断被提拔。他获得伦敦大学（ London University）医疗资格、利兹大学（the University of Leeds）的分子医学博士学位以及英国 the Open Business School的工商管理硕士学位。他是the Royal College of Pediatrics 和Child Health Physicians UK的成员以及在儿科和儿童肿瘤进行学习的研究生。他目前是德州的癌症预防研究所（the Cancer Prevention Research Institute of Texas，癌症研究和预防项目和服务的基金）商业化审查委员会（the Commercialization Review Council）成员。
Adam R. Craig has served as one of our directors and as our President and Chief Executive Officer since March 2017. Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012 Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. Dr. Craig is a Member of the Royal College of Physicians UK and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the UK and an M.B.A. from the Open Business School in the UK. Dr. Craig has served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas.- Adam R. Craig, Ph.D.，2012年3月以来，他一直担任我们的执行副总裁负责发展和首席医疗官。从2007年9月到2011年12月，他担任 ChemGenex Pharmaceuticals Ltd.（一个从事于治疗癌症的新治疗药物的发展的生物科技公司）的首席医疗官和类似职务，随后2011年7月公司被ChemGenex by Cephalon, Inc.收购。2011年10月Cephalon, Inc.被 Teva Pharmaceutical Industries Ltd.收购。从2011年12月到加入公司，他担任Teva Pharmaceutical Industries Ltd.的顾问。在加入ChemGenex之前，他是Innovive Pharmaceuticals, Inc.（从事血液学公司）的创始首席医疗官。在加入 Innovive之前，他担任ArQule Inc.、Ilex Oncology Inc.和Antisoma plc。担任职务并不断被提拔。他获得伦敦大学（ London University）医疗资格、利兹大学（the University of Leeds）的分子医学博士学位以及英国 the Open Business School的工商管理硕士学位。他是the Royal College of Pediatrics 和Child Health Physicians UK的成员以及在儿科和儿童肿瘤进行学习的研究生。他目前是德州的癌症预防研究所（the Cancer Prevention Research Institute of Texas，癌症研究和预防项目和服务的基金）商业化审查委员会（the Commercialization Review Council）成员。
- Adam R. Craig has served as one of our directors and as our President and Chief Executive Officer since March 2017. Dr. Craig worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016. From 2008 to 2012 Dr. Craig was Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd, a biotechnology company which was acquired by Cephalon/Teva Pharmaceuticals in 2011. Dr. Craig is a Member of the Royal College of Physicians UK and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from Charing Cross and Westminster Medical School, University of London, and holds a Ph.D. in Molecular Oncology from Leeds University in the UK and an M.B.A. from the Open Business School in the UK. Dr. Craig has served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas.
- Bruce J. Seeley
Bruce J. Seeley自2012年5月担任诊断部门的高级副总裁和总经理。在加入我公司前，Seeley先生从2009年10月到2012年3月，担任Seattle Genetics负责商业运营的执行副总裁，该公司是一家上市的生物技术公司。在Seattle Genetics任职期间，Seeley先生建立并领导了商业组织，同时成功地推出了Seattle Genetics的第一个产品，即ADCETRIS，这是淋巴瘤的定向治疗法。在加入Seattle Genetics前，Seeley先生从2004年8月到2009年10月在Genentech, Inc.担任各种商业职务，该公司在2009年3月被Roche收购。从2006年到2009年，他担任负责市场营销的高级董事，任职期间，他领导了HERCEPTIN（乳腺癌辅药）的开发。从2004年到2006年，他担任Genentech负责管道品牌管理和生物肿瘤业务单元运营的高级董事，同时领导策略和跨经销权商业活动。从2000年到2004年，Seeley先生任职于Aventis Pharmaceuticals，该公司是一家上市的全球制药公司，他担任的职务的职责逐渐增加，包括担任负责新产品商业化和认证以及肿瘤全球市场营销部门的高级董事。在加入Aventis前，他在Rhone-Poulenc Rorer和Bristol-Myers Squibb担任各种市场营销和销售职务，前者是一家上市的全球制药公司；后者是一家上市的生物制药公司。Seeley销售从加州大学洛杉矶分校（University of California at Los Angeles）获得社会学学士学位。
Bruce J. Seeley assumed his role as our as Executive Vice President and Chief Operating Officer in September 2017. He joined us in July 2015 as Executive Vice President and Chief Commercial Officer. Mr. Seeley previously served as Senior Vice President and General Manager, Diagnostics at NanoString Technologies, Inc. from May 2012 to March 2015. From October 2009 to March 2012 Mr. Seeley was Executive Vice President, Commercial, at Seattle Genetics, Inc. Prior to that, from August 2004 to October 2009 Mr. Seeley served in various commercial roles at Genentech, Inc. now a member of the Roche Group. From 1996 to 2004 Mr. Seeley held various roles at Aventis Pharmaceuticals Inc. (now a part of Sanofi) in global and U.S. marketing, sales and new product commercialization and licensing. Prior to that, from 1991 to 1996 he served in sales at Bristol-Myers Squibb Company. Mr. Seeley received a B.A. in Sociology from the University of California at Los Angeles.- Bruce J. Seeley自2012年5月担任诊断部门的高级副总裁和总经理。在加入我公司前，Seeley先生从2009年10月到2012年3月，担任Seattle Genetics负责商业运营的执行副总裁，该公司是一家上市的生物技术公司。在Seattle Genetics任职期间，Seeley先生建立并领导了商业组织，同时成功地推出了Seattle Genetics的第一个产品，即ADCETRIS，这是淋巴瘤的定向治疗法。在加入Seattle Genetics前，Seeley先生从2004年8月到2009年10月在Genentech, Inc.担任各种商业职务，该公司在2009年3月被Roche收购。从2006年到2009年，他担任负责市场营销的高级董事，任职期间，他领导了HERCEPTIN（乳腺癌辅药）的开发。从2004年到2006年，他担任Genentech负责管道品牌管理和生物肿瘤业务单元运营的高级董事，同时领导策略和跨经销权商业活动。从2000年到2004年，Seeley先生任职于Aventis Pharmaceuticals，该公司是一家上市的全球制药公司，他担任的职务的职责逐渐增加，包括担任负责新产品商业化和认证以及肿瘤全球市场营销部门的高级董事。在加入Aventis前，他在Rhone-Poulenc Rorer和Bristol-Myers Squibb担任各种市场营销和销售职务，前者是一家上市的全球制药公司；后者是一家上市的生物制药公司。Seeley销售从加州大学洛杉矶分校（University of California at Los Angeles）获得社会学学士学位。
- Bruce J. Seeley assumed his role as our as Executive Vice President and Chief Operating Officer in September 2017. He joined us in July 2015 as Executive Vice President and Chief Commercial Officer. Mr. Seeley previously served as Senior Vice President and General Manager, Diagnostics at NanoString Technologies, Inc. from May 2012 to March 2015. From October 2009 to March 2012 Mr. Seeley was Executive Vice President, Commercial, at Seattle Genetics, Inc. Prior to that, from August 2004 to October 2009 Mr. Seeley served in various commercial roles at Genentech, Inc. now a member of the Roche Group. From 1996 to 2004 Mr. Seeley held various roles at Aventis Pharmaceuticals Inc. (now a part of Sanofi) in global and U.S. marketing, sales and new product commercialization and licensing. Prior to that, from 1991 to 1996 he served in sales at Bristol-Myers Squibb Company. Mr. Seeley received a B.A. in Sociology from the University of California at Los Angeles.